SHINE Presents at 2017 Mo-99 Topical Meeting

Katrina Pitas, VP, Business Development

Katrina Pitas, VP, Business Development

September 1, 2017  – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that the company has been invited to speak at the 2017 Mo-99 Topical Meeting hosted by the Department of Energy’s National Nuclear Security Administration (DOE/NNSA).

Held in Montreal, Quebec, Canada from September 10-14, the DOE/NNSA Mo‑99 Topical Meeting is a discussion forum for regulatory, policy and technical experts working toward a reliable global supply of molybdenum-99 (Mo-99) produced without the use of highly-enriched uranium.  At the meeting, Katrina Pitas, VP, Business Development, will present an overview of SHINE’s groundbreaking Mo-99 production technology and provide an update on the status of the SHINE project.

About Mo-99

Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99.

About SHINE Medical Technologies, Inc.

Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99.  In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals.  Learn more at http://SHINEmed.com.